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ABSTRACT
Background: Hereditary transthyretin (ATTRm) amyloidosis is a rare, progressive and fatal disease with
a range of clinical manifestations.
Objective: This study comprehensively evaluates disease characteristics in a large, diverse cohort of
patients with ATTRm amyloidosis.
Methods: Adult patients (N¼ 172) with Stage 1 or Stage 2 ATTRm amyloidosis who had polyneurop-
athy were screened and enrolled across 24 investigative sites and 10 countries in the NEURO-TTR trial
(www.clinicaltrials.gov, NCT01737398). Medical and disease history, quality of life, laboratory data, and
clinical assessments were analyzed.
Results: The NEURO-TTR patient population was diverse in age, disease severity, TTR mutation, and
organ involvement. Twenty-seven different TTR mutations were present, with Val30Met being the
most common (52%). One third of patients reported early onset disease (before age 50) and the aver-
age duration of neuropathy symptoms was 5.3 years. Symptoms affected multiple organs and systems,
with nearly 70% of patients exhibiting broad involvement of weakness, sensory loss, and autonomic
disturbance. Over 60% of patients had cardiomyopathy, with highest prevalence in the United States
(72%) and lowest in South America/Australasia (33%). Cardiac biomarker NT-proBNP correlated with
left ventricular wall thickness (p<.001). Quality of life, measured by Norfolk QoL-DN and SF-36 patient-
reported questionnaires, was significantly impaired and correlated with disease severity.
Conclusions: Baseline data from the NEURO-TTR trial demonstrates ATTRm amyloidosis as a systemic
disease with deficits in multiple organs and body systems, leading to decreased quality of life. We
report concomitant presentation of polyneuropathy and cardiomyopathy in most patients, and early
involvement of multiple body systems.
Abbreviations: Echo: echocardiogram; eGFR: estimated glomerular filtration rate; EU: Europe; GI:
gastrointestinal; GLS: global longitudinal strain; Hgb: hemoglobin; HP: heat as pain; HRDB: heart rate
with deep breathing; hsCRP: high-sensitivity C-reactive protein; LLN: lower limit of normal; LV: left ven-
tricle; mNIS þ7: modified neuropathy impairment score; NCV: nerve conduction velocity; NIS: neur-
opathy impairment score; NSC: neuropathy symptoms and change score; NYHA: New York Heart
Association; NT-proBNP: n-terminal pro-hormone brain natriuretic peptide; P/C: protein/creatinine ratio;
PCS: physical component summary; PND: polyneuropathy disability score; QoL: quality of life; RBC: red
blood cells; SA: South America/Australasia; TP: touch-pressure; TTR: transthyretin; ULN: upper limit of
normal; US: United States
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Introduction
Transthyretin (TTR) is a 55 kDa protein composed of four
identical subunits, primarily synthesized in the liver and
secreted into the plasma as a transporter of thyroxine (T4)
and retinol (vitamin A). Hereditary transthyretin (ATTRm)
amyloidosis is a rare, systemic, autosomal dominant genetic
disorder caused by mutations in the TTR gene with an
estimated 50,000 patients world-wide [1]. These mutations
destabilize the normal tetrameric structure of TTR causing
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dissociation into free monomers. The free monomers
aggregate into insoluble fibrils which deposit as amyloid
on tissues in multiple organs, including the peripheral ner-
vous system, gastrointestinal (GI) tract, heart, kidneys, and
eyes, resulting in local cell damage. Historically, the disease
has been described as either a polyneuropathy when per-
ipheral nerves are predominantly involved or
a cardiomyopathy when the heart is predominantly
affected. However, ATTRm amyloidosis is a single, sys-
temic disease presenting with a wide spectrum of manifes-
tations that frequently includes both nerve and heart
involvement [2].
A major clinical manifestation of ATTRm amyloidosis is
intractable peripheral sensorimotor and autonomic neur-
opathy. Sensory neuropathy first presents in the lower
extremities, with paresthesia and hypoesthesia followed by
neuropathic pain of the feet [3]. Gastrointestinal symptoms
of diarrhea and/or profound constipation often follow,
reflecting autonomic dysfunction [4,5]. Motor neuropathy
results in mobility impairment. In patients with cardiomy-
opathy, TTR amyloid fibrils infiltrate the myocardium,
which can result in diastolic dysfunction progressing
to restrictive cardiomyopathy and heart failure [6]. A sub-
set of patients will develop renal deposits, often with
microalbuminuria as the initial presentation occurring
within 3–5 years of disease onset, and progressing to renal
failure 5 years after microalbuminuria [7,8]. Life expect-
ancy ranges from 3 to 15 years, with poorer prognosis
when cardiomyopathy is present [1,9]. The most common
causes of death are malnutrition and cachexia, renal fail-
ure, or cardiac disease [10].
There are over 100 amyloidosis-associated TTR muta-
tions identified. One of the most common mutations,
Val30Met, accounts for 50% of ATTRm amyloidosis
worldwide [11]. The prevalence of this mutation, however,
varies greatly depending on geographical region [12,13]. The
age of polyneuropathy symptom onset has been described as
bimodal, with one peak in the third to fourth decade of life,
and the other in the sixth decade [14]. Age of onset is also
associated with the underlying TTR gene mutation and the
geographical origin of the patient [15,16]. Individuals with
TTR gene mutations that are predominantly associated with
late onset disease (after age 50), have more cardiac abnor-
malities and a shorter overall life expectancy than those
diagnosed with early onset disease (before age
50) [12,17,18].
This study describes the baseline demographic and dis-
ease characteristics of participants enrolled in NEURO-TTR,
an international randomized, placebo-controlled 15-month
phase 3 clinical trial evaluating the efficacy and safety of
inotersen in patients with ATTRm amyloidosis [19].
Inotersen is a second-generation antisense oligonucleotide
(ASO) inhibitor of both mutant and wild type TTR produc-
tion [20].
The depth of information from the NEURO-TTR trial
provides the opportunity to describe the disease manifesta-
tions of this rare disease in a relatively large ATTRm cohort
from endemic and non-endemic regions of the world.
Disease characteristics were assessed by genotype, geograph-
ical region, disease onset and duration, quality of life (QoL),
and symptom manifestation.
Methods
Trial design and oversight
NEURO-TTR was a randomized, placebo-controlled, phase 3
trial designed to evaluate the efficacy and safety of inotersen
in patients with ATTRm polyneuropathy and conducted at 24
sites worldwide from March 2013 to November 2017. The
protocol was approved by each site’s institutional review
board or independent ethics committee. The trial was per-
formed in compliance with the Declaration of Helsinki (2002)
and Good Clinical Practice guidelines. All participants pro-
vided written informed consent before enrollment. Screening
and baseline evaluations were performed during a 6-week
screening and baseline assessment period.
Participants
Male and female participants 18–82 years of age with Stage 1
or 2 ATTRm amyloidosis, a Neuropathy Impairment Score
(NIS) between 10–130, TTR mutation by genotyping, and
biopsy-confirmed amyloid deposits were eligible to partici-
pate in the NEURO-TTR trial. Key exclusion criterion
included New York Heart Association (NYHA) Class III and
higher, previous liver transplant, presence of diabetes mellitus
or other causes of neuropathy, platelets <125 109/L, pro-
teinuria >1.0 g/24 hours, and estimated glomerular filtration
rate (eGFR) calculated by the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EIP) equation as
< 60mL/min/1.73 m2 (platelet and GFR criteria were modi-
fied by protocol amendment).
Baseline data collected
The collected data included demographics, geographic loca-
tion (United States (US), Europe (EU), South America/
Australasia (SA)), TTR mutation, disease and medical his-
tory, cardiac echocardiogram (Echo), NYHA classification
and clinical laboratory tests. Baseline ATTRm disease status
was measured using Coutinho Staging (Stage 1, walk
unaided; Stage 2, walk with aid; Stage 3, wheelchair or bed-
bound) [21], polyneuropathy disability score (PND; Stage I,
sensory disturbances in limbs without motor impairment;
Stage II, difficulty walking without the need of a walking
aid; Stage III, one stick or one crutch required for walking;
Stage IV, two sticks or two crutches needed); and the modi-
fied neuropathy impairment score (mNIS þ7) which con-
sists of two components, the NIS composite score and the
modified þ7 composite score of physiological tests as previ-
ously described [22]. Nerve conduction, quantitative sensa-
tion testing (touch-pressure (TP) and heat as pain (HP)
[22–26]) and heart rate with deep breathing (HRDB) were
part of the modified þ7. Two mNIS þ7 assessments were
performed prior to the first dose of study drug. In order to
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assess the fraction of participants that had demyelinating
features to their neuropathy, the proportion of participants
with fibular nerve conduction velocities <39m/s, a fibular
amplitude >1.0mV and fibular nerve motor distal latency
>5.6ms were determined. Patient-perceived QoL was col-
lected using the Norfolk QoL-DN and SF-36 patient-
reported questionnaires [27,28]. Presence of neuropathy
symptoms was also measured with the Neuropathy
Symptoms and Change Score (NSC) score which is a phys-
ician administered questionnaire of the patient’s neuropathy
symptoms [29]. The NSC captures the presence and severity
of four broad neuropathy symptom categories (muscle
weakness (W), sensory loss (S), positive neuropathic sensory
symptoms, including pain (P) and autonomic symp-
toms (A)).
Statistical analysis
This baseline characteristics study was performed on all eli-
gible randomized participants. Statistical significance was
determined by analysis of variance (ANOVA) and two-sam-
ple t-test with two-sided significance level of 0.05. Software
utilized for the analyses was SAS version 9.3 or higher (SAS
Institute, Cary, NC, USA).
Results
Demographics and disease baseline characteristics
The trial enrolled and dosed 172 participants with ATTRm
amyloidosis across 10 countries; United States (n¼ 82),
Portugal (n¼ 24), France (n¼ 15), Italy (n¼ 8), UK (n¼ 6),
Spain (n¼ 4), Germany (n¼ 3), Brazil (n¼ 22), Argentina
(n¼ 7) and New Zealand (n¼ 1). The study population was
diverse with respect to age, TTR mutation, disease severity
by neurological assessments and QoL, and organ involve-
ment, reflecting the broad heterogeneity of patients with
ATTRm amyloidosis worldwide (Table 1). The mean age of
the cohort was 59 years, ranging from 27–81 years. The old-
est and youngest patients both had Val30Met mutation,
demonstrating diversity of presentation even within the
same mutation. Approximately 60% of patients had prior
treatment with TTR stabilizers (tafamidis or diflunisal) and
40% were treatment-naïve. One third of the cohort reported
early onset of disease symptoms, and the average duration
of neuropathy symptoms was 5.3 years. The mNIS þ7 score
ranged from 11–175 with about 1/3 of patients reporting no
ambulatory disability (PND score I), 1/3 with some walking
impairment (PND score II) and 1/3 requiring either one or
two walking aids (PND score III–IV). Over 60% of patients
had concomitant cardiomyopathy.
The mean ages across geographical regions were 65, 57
and 49 years for US, EU and SA respectively, with the US
subgroup significantly older than either EU or SA (vs. EU,
p<.001 and vs. SA, p<.001). The proportion of early onset
patients varied by geographical region with over 60% of
patients from SA with early onset disease (US 16%; EU
40%; SA 63%). The use of TTR stabilizers corresponded
with standard of care and availability of these treatments in
the different geographical regions. Previous treatment with
tafamidis was more prevalent in the EU population (43
[72%] patients), while the majority of those treated with
diflunisal were from the US (41 [50%] patients). SA patients,
by contrast, were largely treatment-naïve (21 [70%]
patients). Presence of cardiomyopathy was high in US
patients (77%), compared with EU (57%) and SA (37%).
Despite these differences, disease stage, duration of symp-
toms, and mean mNIS þ7 scores were similar across geo-
graphic regions.
Comparing early versus late onset patients, late onset
patients had shorter disease duration, were mostly males,
and had a high frequency of cardiomyopathy. Early onset
patients were more likely to be Stage 1, Val30Met, with
lower PND scores and no cardiomyopathy. Patients who
were previously treated with TTR stabilizers had longer dis-
ease duration compared to treatment-naïve patients, but
were otherwise similar in age and disease stage and onset
(Table 1).
A total of 27 TTR mutations were represented in this
study population (Supplemental Figure S1). The most com-
mon mutation was Val30Met, occurring in 52% of patients,
followed by Thr60Ala (13%), Leu58His (6%), Ser77Tyr
(5%), and Phe64Leu (5%). Of the mutations with 5%
prevalence in NEURO-TTR, patients with Phe64Leu were
the oldest, all male, had the lowest frequency of cardiomy-
opathy, while patients with Ser77Tyr were the youngest,
mostly female, and had the highest frequency of cardiomy-
opathy (Table 2). Comparing the Val30Met patients to the
non-Val30Met patients, overall non-Val30Met patients were
older with a higher frequency of late onset disease and car-
diomyopathy. The prevalence of the Val30Met mutation was
highest in SA (93%), with the US having the most genotypic
diversity (26% Val30Met with 20 other genotypes repre-
sented), while diversity in the EU varied depending on
country. Portugal had almost exclusively Val30Met whereas
other countries had more diversity in TTR mutations.
Disease manifestations
Sensory, motor and autonomic neuropathy
Clinical baseline sensory, motor, and autonomic neuropathy
status was assessed by the NSC score and mNIS þ7 com-
posite score. Components of each score were examined rela-
tive to TTR mutation. At baseline, 70% of patients exhibited
symptoms associated with all four neuropathy categories,
and another 19% exhibited muscle weakness plus two other
categories (W-S-P, W-P-A, and W-S-A). These data suggest
a broad involvement of weakness, sensory loss and auto-
nomic disturbance. Similar results were seen when analyzed
by mutation status (Table 2), noting that Thr60Ala and
Ser77Tyr mutations had a higher percentage of patients
with autonomic involvement. When the symptom category
was examined by PND status, it showed approximately 50%
of PND I patients already had a pan-modality of symptoms
and this increased to 70% in PND II and almost 90% in
PND III/IV (Supplemental Figure S2).
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Severity of muscle weakness and sensation loss as
assessed by the NIS muscle weakness component and TP
quantitative sensation (large fiber) showed roughly equal
deficits across the mutation groups. However, HP sensation
(small fiber) assessment showed that early onset Val30Met
patients had a statistically significant increased deficit versus
the late onset Val30Met patients, Thr60Ala, or other
mutations combined (data not shown). These data suggest
that early onset Val30Met patients have a higher prevalence
of small fiber deficits versus late onset Val30Met patients.
Examination of nerve conduction showed only three
patients with demyelinating features present in the fibular
nerve. This is consistent with demyelinating neuropathy
being uncommon in ATTRm with polyneuropathy. The
Table 1. Demographics and baseline characteristics by region, disease onset and prior treatment with TTR Stabilizers.
Region Disease onset Prior treatment
Total
(n¼ 172)
US
(n¼ 82)
Europe
(n¼ 60)
SA
(n¼ 30)
Early
(n¼ 56)
Late
(n¼ 116)
Stabilizers
(n¼ 99)
Naïve
(n¼ 73)
Age, yrs
Mean (SD) 59.2 (13.0) 64.6 (8.7) 57.0 (13.8) 48.6 (13.9) 43.8 (9.3) 66.6 (6.3) 59.8 (13.2) 59.7 (13.0)
Min–Max 27–81 40–78 27–81 28–73 27–70 53–81 28–81 27–78
Sex
Male, n (%) 118 (69%) 61 (74%) 39 (65%) 18 (60%) 33 (59%) 85 (73%) 65 (66%) 53 (73%)
mBMIa, kg/m2 g/L
Mean (SD) 1025 (228) 1050 (245) 1008 (210) 986 (213) 989 (235) 1041 (224) 1034 (222) 1012 (238)
Min–Max 573–1752 573–1752 685–1687 669–1405 669–1710 573–1752 573–1752 630–1710
BP, mm Hg
Mean, SBP / DBP 121 / 76 122 / 76 123 / 78 116 / 72 115 / 74 124 / 77 123 / 77 118 / 74
TTR, mg/dL
Mean (SD) 21.5 (5.6) 20.5 (5.4) 21.7 (5.4) 23.7 (6.3) 22.0 (5.7) 21.2 (5.6) 22.5 (4.9) 20.1 (6.2)
Min–Max 8.6–39.7 9.6–35.3 8.6–33.4 11.8–39.7 11.8–39.7 8.6–33.4 9.8–35.3 8.6–39.7
TTR Mutation, n (%)
Val30Met 89 (52%) 21 (26%) 40 (67%) 28 (93%) 40 (71%) 49 (42%) 52 (53%) 37 (51%)
Prior Treatment, n (%)
Tafamidis 53 (31%) 3 (4%) 43 (72%) 7 (23%) 28 (50%) 25 (22%) 53 (54%) 0 (0%)
Diflunisal 49 (28%) 41 (50%) 6 (10%) 2 (7%) 6 (11%) 43 (37%) 49 (49%) 0 (0%)
None 73 (42%) 39 (48%) 13 (22%) 21 (70%) 22 (39%) 51 (44%) 0 (0%) 73 (100%)
Disease stageb, n (%)
Stage 1 116 (67%) 57 (70%) 38 (63%) 21 (70%) 44 (79%) 72 (62%) 68 (69%) 48 (66%)
Stage 2 56 (33%) 25 (30%) 22 (37%) 9 (30%) 12 (21%) 44 (38%) 31 (31%) 25 (34%)
Disease onsetc, n (%)
Early 56 (33%) 13 (16%) 24 (40%) 19 (63%) 56 (100%) 0 (0%) 34 (34%) 22 (30%)
Duration of symptomsd, yrs
Mean (SD) 5.3 (4.4) 5.7 (5.7) 5.3 (2.7) 4.3 (2.4) 6.6 (5.4) 4.7 (3.7) 5.9 (4.3) 4.6 (4.4)
Presence of CMe,
n (%)
108 (63%) 63 (77%) 34 (57%) 11 (37%) 20 (36%) 88 (76%) 60 (61%) 48 (66%)
NYHAf, n (%)
I 111 (65%) 55 (67%) 33 (55%) 23 (77%) 45 (80%) 66 (57%) 67 (68%) 44 (60%)
II 61 (35%) 27 (33%) 27 (45%) 7 (23%) 11 (20%) 50 (43%) 32 (32%) 29 (40%)
NT-proBNP, pg/mL
Mean (SD) 910 (1916) 1023 (1470) 1027 (2693) 362 (467) 354 (569) 1181 (2256) 665 (1103) 1254 (2640)
Min–Max 11–19084 31–7198 11–19,084 21–1743 11–2499 21–19,084 11–7387 21–19,084
mNIS þ7
Mean (SD) 78 (38) 71 (36) 88 (33) 76 (47) 79 (38) 77 (37) 81 (36) 73 (39)
(Min–Max) (11–175) (11–175) (30–169) (13–160) (13–160) (11–175) 11–175 13–165
NSCg, n (%)
W-P-S-A 120 (70%) 55 (67%) 46 (77%) 19 (63%) 40 (71%) 80 (69%) 68 (69%) 52 (71%)
W-S-P 18 (10%) 10 (12%) 5 (8%) 3 (10%) 6 (11%) 12 (10%) 15 (15%) 3 (4%)
W-P-A 11 (6%) 6 (7%) 3 (5%) 2 (7%) 1 (2%) 10 (9%) 3 (3%) 8 (11%)
W-S-A 5 (3%) 2 (2%) 2 (3%) 1 (3%) 3 (5%) 2 (2%) 3 (3%) 2 (3%)
S-P-A 3 (2%) 0 (0%) 2 (3%) 1 (3%) 2 (4%) 1 (1%) 1 (1%) 2 (3%)
Other 15 (9%) 9 (11%) 2 (3%) 4 (13%) 4 (7%) 11 (9%) 9 (9%) 6 (8%)
PND, n (%)
I 55 (32%) 35 (43%) 10 (17%) 10 (33%) 16 (29%) 39 (34%) 26 (26%) 29 (40%)
II 61 (35%) 22 (27%) 28 (47%) 11 (37%) 28 (50%) 33 (28%) 42 (42%) 19 (26%)
III 45 (26%) 21 (26%) 18 (30%) 6 (20%) 9 (16%) 36 (31%) 28 (28%) 17 (23%)
IV 11 (6%) 4 (5%) 4 (7%) 3 (10%) 3 (5%) 8 (7%) 3 (3%) 8 (11%)
aModified BMI (mBMI) adjusts for serum albumin
bStage I does not require assistance with ambulation, Stage II requires assistance with ambulation
cDisease symptoms before age 50 (calculated by age minus years with symptoms).
dDuration of symptoms calculated as time between symptom onset and ICF date.
ePresence of cardiomyopathy was defined by a diagnosis of TTR cardiomyopathy at study entry and/or by the following criteria: interventricular wall thickness
of 13mm on transthoracic ECHO at baseline as ascertained by a central reader, no known history of persistent hypertension 150mmHg within 12 months
prior to screening.
fStudy excluded NYHA III and higher
gNeuropathy Symptom and Change (NSC) domain categories: Muscle Weakness (W), Sensory Loss (S), Positive Neuropathy Sensory Symptoms (P), Autonomic
(A). Other includes combinations of 2 domains (P-A, W-A, W-P, S-P) or a single domains (A).
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reduction in nerve conduction velocity (NCV) was mild in
those patients with an average fibular NCV of 37.0 ± 0.5 m/s
and distal motor latency (DML) of 6.0 ± 0.3ms.
Presence of autonomic neuropathy, as reported by
patients, was consistent with the NSC results. Over 50% of
patients had a history of gastrointestinal manifestations,
which are generally attributed to deficits in the autonomic
nervous system. GI amyloidosis or symptoms, such as recur-
ring diarrhea, constipation, defecation urgency, GI mobility
disorder, or GI hypomotility were reported in 80 (47%)
Table 2. Baseline characteristics by TTR mutation (>¼5% prevalence in NEURO-TTR).
Total
(n¼ 172)
Val30Met
(n¼ 89)
Non-Val30Met
(n¼ 83)
Thr60Ala
(n¼ 22)
Leu58His
(n¼ 10)
Ser77Tyr
(n¼ 9)
Phe64Leu
(n¼ 8)
Regiona
United States 82 (48%) 21 (24%) 61 (73%) 19 (86%) 10 (100%) 2 (22%) 7 (88%)
Europe 60 (35%) 40 (45%) 20 (24%) 2 (9%) 0 (0%) 6 (67%) 1 (13%)
South America 30 (17%) 28 (31%) 2 (2%) 1 (5%) 0 (0%) 1 (11%) 0 (0%)
Age, yrs
Mean (SD) 59.2 (13.0) 55.5 (15.2) 63.1 (8.8) 65.8 (6.5) 65.3 (7.8) 62.4 (4.0) 69.4 (4.7)
Min–Max 27–81 27–81 40–78 52–78 52–75 55–68 59–74
Sex
Male, n (%) 118 (69%) 63 (71%) 55 (66%) 17 (77%) 6 (60%) 5 (6%) 8 (100%)
mBMIb, kg/m2 g/L
Mean (SD) 1025 (228) 1003 (209) 1047 (246) 1081 (305) 1206 (177) 1005 (205) 1036 (157)
Min–Max 573–1752 573–1687 630–1752 630–1710 883–1450 817–1388 775–1257
BP, mmHg
Mean, SBP/DBP 121 / 76 120 / 75 123 / 76 123 / 76 133 / 81 122 / 80 123 / 78
TTR, mg/dL
Mean (SD) 21.5 (5.6) 22.9 (5.3) 20.0 (5.6) 20.3 (5.8) 24.2 (5.8) 19.4 (4.9) 18.9 (3.4)
Min–Max 8.6–39.7 11.8–39.7 8.6–35.3 9.6–30.1 15.2–35.3 10.6–26.4 13.5–23.7
Prior Treatment, n (%)
Tafamidis 53 (31%) 40 (45%) 13 (16%) 0 (0%) 1 (10%) 4 (44%) 0 (0%)
Diflunisal 49 (28%) 14 (16%) 35 (42%) 11 (50%) 7 (70%) 2 (22%) 4 (50%)
None 73 (42%) 37 (42%) 36 (43%) 11 (50%) 2 (20%) 3 (33%) 4 (50%)
Disease stagec, n (%)
Stage 1 116 (67%) 59 (66%) 57 (69%) 17 (77%) 5 (50%) 7 (78%) 5 (63%)
Stage 2 56 (33%) 30 (34%) 26 (31%) 5 (23%) 5 (50%) 2 (22%) 3 (38%)
Disease onsetd, n (%)
Early onset 56 (33%) 40 (45%) 16 (19%) 3 (14%) 2 (20%) 0 (0%) 0 (0%)
Duration of symptomse, yrs
Mean (SD) 5.3 (4.4) 5.3 (3.9) 5.4 (4.9) 5.4 (4.4) 6.0 (7.5) 4.6 (2.5) 5.2 (2.1)
Presence of CMf, n (%) 108 (63%) 43 (48%) 65 (78%) 20 (91%) 4 (40%) 9 (100%) 3 (38%)
NYHAg, n (%)
I 111 (65%) 67 (75%) 44 (53%) 10 (45%) 9 (90%) 3 (33%) 5 (63%)
II 61 (35%) 22 (25%) 39 (47%) 12 (55%) 1 (10%) 6 (67%) 3 (38%)
NT-proBNP, pg/mL
Mean (SD) 910 (1916) 829 (2332) 997 (1343) 1563 (1689) 192 (125) 641 (509) 234 (174)
Min–Max 11–19,084 11–19,084 31–7036 83–7036 37–432 207–1615 31–495
mNIS þ7
Mean (SD) 78 (38) 81 (39) 74 (36) 63 (32) 83 (37) 77 (28) 97 (34)
Min–Max 11–175 11–175 14–169 14–160 35–131 45–115 67–165
NSCh, n (%)
W-P-S-A 120 (70%) 61 (69%) 59 (71%) 15 (68%) 5 (50%) 6 (67%) 7 (88%)
W-S-P 18 (10%) 10 (11%) 8 (10%) 1 (5%) 3 (30%) 0 (0%) 1 (13%)
W-P-A 11 (6%) 2 (2%) 9 (11%) 4 (18%) 0 (0%) 3 (33%) 0 (0%)
W-S-A 5 (3%) 5 (6%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
S-P-A 3 (2%) 3 (3%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Others 15 (9%) 8 (9%) 7 (8%) 2 (9%) 2 (20%) 0 (0%) 0 (0%)
PND Score, n (%)
I 55 (32%) 19 (21%) 36 (43%) 12 (55%) 3 (30%) 2 (22%) 2 (25%)
II 61 (35%) 40 (45%) 21 (25%) 5 (23%) 2 (20%) 5 (56%) 3 (38%)
III 45 (26%) 23 (26%) 22 (27%) 4 (18%) 4 (40%) 2 (22%) 1 (13%)
IV 11 (6%) 7 (8%) 4 (5%) 1 (5%) 1 (10%) 0 (0%) 2 (25%)
aUS: Ala97Ser, Asp38Ala, Glu54Ser, Glu89Gln, Gly67Arg, Ile107Val, Ile84Ser, Leu58His, Lys35Thr, Lys79Asn, Phe33Leu, Phe64Leu, Pro24Ser, Ser50Arg, Ser77Tyr,
Thr49Ala, Thr59Lys, Thr60Ala, Tyr114Cys, Val30Met, Val122Ile; Europe: Ala109Ser, Glu61Lys, Glu89Gln, Glu89Lys, Gly47Ala, Ile107Phe, Phe64Leu, Ser77Phe,
Ser77Tyr, Thr49Ala, Thr60Ala, Val30Met; SA: Ser77Tyr, Thr60Ala, Val30Met.
bModified BMI (mBMI) adjusts for serum albumin
cStage I does not require assistance with ambulation, Stage II requires assistance with ambulation
dDisease symptoms before age 50 (calculated by age minus years with symptoms).
eDuration of symptoms calculated as time between symptom onset and ICF date.
fPresence of cardiomyopathy was defined by a diagnosis of TTR cardiomyopathy at study entry and/or by the following criteria: interventricular wall thickness of
13mm on transthoracic ECHO at baseline as ascertained by a central reader, no known history of persistent hypertension 150mmHg within 12 months prior
to screening.
gStudy excluded NYHA III and higher
hNeuropathy Symptom and Change (NSC) domain categories: Muscle Weakness (W), Sensory Loss (S), Positive Neuropathy Sensory Symptoms (P), Autonomic
(A). Other includes combinations of 2 domains (P-A, W-A, W-P, S-P) or single domains (A).
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patients; nausea, vomiting, or early satiety in 23 (13%)
patients; and unintentional weight loss (abnormal loss of
weight, weight decreased, cachexia, decreased appetite) in 31
(18%) patients. In addition, 61 (35%) patients reported a
history of either orthostatic hypotension, sexual dysfunction,
urinary tract infection (UTI), urinary retention/hesitation/
incontinence or neurogenic bladder.
Cardiomyopathy and conduction abnormalities
Sixty three percent of patients had cardiomyopathy, includ-
ing 19% with implanted pacemakers, and 21% reporting a
history of cardiac blocks, atrial fibrillation and arrhythmia.
An analysis of ECGs collected at baseline showed 40% of
patients with abnormalities; the most common being left
axis deviation/inferior infarct pattern, first degree heart
block, and anterior infarct pattern. Interestingly, low-voltage
was less common in this population (observed in about 10%
of the patients) compared with previous reports (25% Italian
ATTRm amyloidosis population) [30].
Levels of N-terminal pro-hormone brain natriuretic pep-
tide (NT-proBNP) correlates with LV dysfunction and can
be used for early detection of cardiac impairment in patients
with ATTRm amyloidosis [31]. NT-proBNP tracked with
cardiac involvement and varied considerably by mutation.
Val30Met early onset had lower levels versus Val30Met late
onset, consistent with a higher degree of cardiomyopathy in
the latter group. Thr60Ala, known to have significant car-
diac involvement [13,32], showed one of the highest average
NT-proBNP levels. There was a positive correlation between
increased NT-proBNP concentrations and increased left
ventricle (LV) wall thickness (p<.0001) (Figure 1). LV mass
and NT-proBNP also showed strong positive correlations
with global longitudinal strain (GLS) (p<.0001, r¼ 0.61; and
p<.0001, r¼ 0.56 respectively), with increases in each par-
ameter corresponding to increased or worse GLS (data
not shown).
Laboratory abnormalities
Laboratory tests were assessed by geography, disease onset,
and prior treatment (Supplemental Table S1), and TTR
mutation (Supplemental Table S2). Low red blood cells
(RBC) and hemoglobin (Hgb) levels were noted in many
patients, with 41 (24%) and 49 (28%) patients below LLN at
baseline, respectively. There were 32 (19%) patients with
baseline high-sensitivity C-reactive protein (hsCRP) values
above the upper limit of normal (ULN, 3mg/L) with the
mean value of 3.8mg/L. Creatine kinase (CK) and high-sen-
sitivity C-reactive protein (hsCRP) were higher in Val30Met
and early onset patients.
Mild to moderate renal impairment and proteinuria as
assessed by laboratory tests was common, especially in
Val30Met patients. The mean eGFR was 88.4mL/min/
1.73 m2, with 14 of 172 (8%) of patients below the LLN at
baseline (normal range >60mL/min/1.73 m2), and lower
mean eGFR in subgroups associated with older patients (i.e.,
US and late onset). The mean urine albumin/creatinine (A/
C) ratio at baseline was 51.6 mg/g (normal range 0–16
male, 0–24 female) and mean urine protein/creatinine (P/C)
ratio was 187.5mg/g (normal range <200), with 59 of 172
(34%) patients above the ULN for one or both ratios. 41 of
59 patients who had A/C or P/C ratio>ULN, and 6 of 10
patients with >500mg urine protein/24-hr had the
Val30Met mutation.
Other assessments
Based on medical history, 34% of patients had a history of
carpal tunnel syndrome and 14% of patients had ocular
involvement based on the reported terms.
Quality of life characteristics
Patient-reported outcomes were used to assess patient-per-
ceived burden of disease. Baseline QoL was evaluated
though two instruments, the Norfolk QoL-DN and SF-36
questionnaires. The Norfolk QoL-DN assesses patient per-
ception of symptoms associated with specific nerve fiber
damage and has been validated in patients with ATTRm
polyneuropathy [27]. The SF-36 is a more general question-
naire to measure overall health status, with the physical
component summary (PCS) indicating overall physical func-
tioning, bodily pain and general physical health [28].
The mean baseline Norfolk QoL-DN and SF-36 (PCS
domain) scores were substantially worse in the NEURO-
TTR cohort compared with controls. The Norfolk QoL-DN
score was 48.4 ± 27.2 compared with 2.6 ± 5.0 for healthy
volunteers (larger scores reflect worse QoL) [27]. The aver-
age SF36 PCS score was 36.3 ± 9.1 compared with 50
reported for the general US population (lower scores reflect
worse QoL) [28]. There was a good correlation between
severity of disease as measured by neuropathy instruments
(mNIS þ7 and PND score) and the patients QoL (Figure 2).
Increased (worse severity) scores for Norfolk QoL-DN sig-
nificantly correlated with increased mNIS þ7 scores
(r¼ 0.54, p<.001). Likewise, increased walking disability
corresponded to decreased (worsening of severity) SF-36
PCS scores (ANOVA overall p<.001; PND I vs II, p¼.016;
PND II vs III, p¼.011; and PND III vs IV, p¼.221).
Subgroup analysis by TTR mutation and symptom onset
(Val30Met early onset, Val30Met late onset, Thr60Ala, or
Figure 1. Relationship of NT-proBNP to LV Septal Wall Thickness.
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others) showed similar trends as the cohort. Finally, there
was a positive correlation between baseline Norfolk QoL-
DN and SF-36 PCS baseline scores (r¼ 0.73, p<.001), with
worse Norfolk QoL-DN scores associated with worse SF-36
PCS scores.
Discussion
Hereditary transthyretin amyloidosis is a rare, progressive,
and fatal disease that presents with a wide spectrum of clin-
ical manifestations, making natural history difficult to accur-
ately describe. Diagnosis can be easily overlooked as patients
often present with common and non-specific symptoms,
and there is limited data on the natural history of ATTRm
amyloidosis [33].
The NEURO-TTR study population reflects the broad
heterogeneity of ATTRm. Detailed neurologic, cardiac, QoL
and lab assessments enabled a detailed analysis of baseline
characteristics in this cohort of 172 diverse ATTRm
patients. Substantial differences in disease characteristics
were noted between patients grouped by either region,
mutation or age of onset. This heterogeneity is consistent
with previous regional, site-specific and disease registry
reports [12,32,34–37] and highlights the challenges
of diagnosis.
Even though many of the patients had early stage neur-
opathy, nearly 70% of patients already had broad involve-
ment of strength, sensation (both large and small fiber
involvement), and autonomic disturbance. The neuropathy
was primarily an axonal neuropathy with little demyelin-
ation being present. Besides neuropathy, there was signifi-
cant cardiovascular, GI, renal and ocular involvement.
Approximately 60% of patients had cardiomyopathy, many
with heavy amyloid burden in the heart as measured by LV
wall thickness. Autonomic dysfunction was broadly seen,
but especially prevalent in the Thr60Ala patients. Renal
impairment is common in patients with ATTRm amyloid-
osis, both as a consequence of cardiac impairment and
amyloid deposits in the kidney [8]. In the NEURO-TTR
cohort, renal amyloidosis was noted to be common in
patients with the Val30Met mutation.
Hereditary ATTR is associated with a substantial disrup-
tion in activities of daily living, including employment rates
and work productivity. In this study two distinct QoL meas-
urements were used to quantitate the impact of ATTRm
amyloidosis. Both instruments showed that in this disease,
QoL was significantly impaired and there was a good correl-
ation between the Norfolk QoL-DN and SF-36 PCS scores.
Both instruments showed a decreased QoL correlated with
clinical progression of polyneuropathy. These data correlate
with previous reports that showed an association between
Norfolk QoL-DN and NIS [22,27]. Caregivers also experi-
ence a large impact on QoL, with increased fatigue and
mental health burden [1]. It will be important to further
explore the impact of QoL not only on patients with
ATTRm amyloidosis, but also on their caregivers.
Data reported here was limited by the NEURO-TTR
study design, and the respective eligibility criteria. While the
cohort was diverse in a number of key demographic param-
eters and disease characteristics, it excluded pre-symptom-
atic and severe ATTRm amyloidosis patients, such as Stage
Figure 2. Quality of Life Corresponds to ATTRm Disease Severity (A) mNIS þ7
composite score increases with worsening Norfolk QoL-DN score. The dotted
horizontal line refers to the average Norfolk QoL-DN score in healthy volunteers
(n¼ 12) [27]. (B) PND stage advances with worsening SF-36 PCS. The dotted
horizontal line refers to the average SF-36 PCS score in the general US popula-
tion [28]. (C) Norfolk Total Score increases with worsening SF-36 PCS.
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3 patients and patients with NYHA III and higher, and was
represented predominantly by Stage 1 patients.
Collectively, the medical history data and clinical and lab
assessments performed at baseline in the NEURO-TTR
study demonstrate a significant impact of ATTRm amyloid-
osis on multiple body systems and organs, as well as a cor-
relation between worsening QoL and disease progression.
This underscores the importance of a holistic approach
to management.
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